20:04 , Aug 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Alt-neoantigens

Neoantigens derived from alternative splicing could broaden the target space for cancer vaccines and T cell therapies, according to two studies published this month. While questions remain about whether they are sufficiently immunogenic to create...
01:27 , Dec 30, 2016 |  BioCentury  |  Emerging Company Profile

Mining for substitutions

Riptide Bioscience Inc. has mined the sequences and structures of failed first-generation peptide therapeutics to engineer a new class of host defense peptides with amino acid substitutions that could make its candidates more effective in...
07:00 , May 5, 2016 |  BC Innovations  |  Targets & Mechanisms

Better call Delilah

Long non-coding RNAs (lncRNAs), once confined to the pile of non-functional genomic "junk," are now recognized to play key roles in gene regulation, and are increasingly being explored in various cancers. A Belgian group has...
07:00 , Jun 30, 2014 |  BC Week In Review  |  Clinical News

DP-VPA regulatory update

D-Pharm said partner Jiangsu NHWA received notice that China Food and Drug Administration (CFDA) granted Fast Track designation to DP-VPA to treat epilepsy. D-Pharm said Jiangsu NHWA plans to begin a Phase I trial in...
07:00 , Jun 17, 2013 |  BC Week In Review  |  Clinical News

Epratuzumab-Rap: Interim Phase I/II data

Interim data from 18 patients in the Phase I portion of an open-label, U.S. Phase I/II trial showed that weekly 200 mg/m 2 IV veltuzumab-RAP for 4 weeks in combination with 2 infusions of...
07:00 , Jun 17, 2013 |  BC Week In Review  |  Clinical News

Veltuzumab-Rap: Interim Phase I/II data

Interim data from 18 patients in the Phase I portion of an open-label, U.S. Phase I/II trial showed that weekly 200 mg/m 2 IV veltuzumab-RAP for 4 weeks in combination with 2 infusions of ...
07:00 , May 7, 2012 |  BC Week In Review  |  Company News

D-Pharm, Jiangsu NHWA deal

D-Pharm received a $1 million milestone payment from Jiangsu NHWA under a 2011 deal that granted Jiangsu NHWA exclusive rights to develop and commercialize DP-VPA in China for epilepsy. The milestone payment is the...
08:00 , Mar 5, 2012 |  BC Week In Review  |  Company News

D-Pharm, Thrombotech deal

D-Pharm said it is in negotiations to acquire stroke company Thrombotech in a stock deal after discontinuing development of its own stroke therapy in January due to lack of efficacy. On Jan. 24, D-Pharm plummeted...
02:16 , Feb 28, 2012 |  BC Extra  |  Company News

D-Pharm seeking Thrombotech acquisition after Phase III halt

D-Pharm Ltd. (Tel Aviv:DPRM) said it is in negotiations to acquire stroke company Thrombotech Ltd. (Ness Ziona, Israel) in a stock deal after discontinuing development of its own stroke therapy last month due to lack...
08:00 , Feb 16, 2012 |  BC Innovations  |  Targets & Mechanisms

Still un-sirtuin

Researchers at the NIH have proposed a new mechanism to explain the beneficial metabolic effects of resveratrol, a polyphenol compound from red wine thought by many to act primarily on sirtuin 1. The NIH team...